Cyteir Therapeutics, Inc.is a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. The company is headquartered in Lexington, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2021-06-18. The firm is focused on developing of CYT-0851, an oral investigational drug candidate that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor (MCT) inhibitor, initially evaluated in a phase I/II study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard of care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy. Its CYT-0851 is also in development in combination with capecitabine and gemcitabine in a Phase I/II clinical study, including patients with advanced ovarian cancer.

Industry: Pharmaceutical Preparations Peers: Black Diamond Therapeutics Inc Bolt Biotherapeutics Inc Cardiff Oncology Inc Equillium Inc Genprex Inc Synlogic Inc Passage Bio Inc TCR2 THERAPEUTICS INC.